The dispute over who invented CRISPR-Cas9 gene editing is headed to federal appellate court, and Politico turned to Professor Jacob Sherkow to help sort out the details. He expects the case will return to patent court and may result in changes to the licensing fees collected. "Absolutely none of this under any reasonable interpretation is going to change what the retail sticker cost of these drug therapies are going to be — not by a dollar, not by a cent," Sherkow added.
Read more from Politico.